Clinical Conditions Associated with Abnormal Hemostasis Flashcards
how common is Von Willebrands Disease?
most common inherited bleeding disorder in North America
1-2% of general population
how do you get Von Willebrand’s Disease?
autosomal trait
recessive trait
what does Von Willebrand’s Factor do?
- mediate platelet adhesion at sites of vascular injury
- binds to and protects Factor VIII from in-vivo proteolysis (the breakdown of protein into amino acids)
deficiency of VWFactor affects
primary hemostasis
what percentage is a mild form of deficiency of VWFactor
> 40% VWF
deficiency of VWFactor is associated with
mucosal bleeding
- epistaxis
- menorrhagia
- bruising
- oral cavity
- GI bleeding
more severe forms of of deficiency of VWFactor
- decrease VWF and decrease Factor VIII
- severe mucosal bleeding
- bleeding into joints and muscles
forms of severe deficiency of Factor VIII
- spontaneous joint bleeds
- retoperitoneal hemorrhage (behind peritoneal: spleen, spine, part of aorta)
- resembles hemophilia
treatment of for deficiency of VWF/Factor VIII
DDAVP (in mild cases): Desmopressin, Stimulating release of the VWF from its storage sites in endothelial cells. Cleaving the large VWF multimers circulating in plasma into smaller multimers.
- plasma products that contain VWF
- adjunct treatments such as anti-fibrinolytic (Amicar) and estrogen
what are some plasma products that contain VWF
- cryoppt
- FVIII/VWF concentrates
- purified VWF
what are congenital plasma coagulation deficiencies
- hemophilia A & B (Factor VIII and IX deficiency)
- Factors XI, X, V, II and I (Fibrinogen)
how is Hemophilia A & B acquired?
- X-linked recessive disorders (woman carries it)
Severity of bleeding for hemophilia A and B
factory activity level
- <1% activity - spontaneous bleeds
- 1-5 % - post-operative and bleeding with minor trauma
- 6-20% - post-operative and with trauma
treatment hemophilia A and B
- replacement with specific factor concentrates
- avoid platelet inhibitory drugs
treatment for Factor XI, X, V, II and I (Fibrinogen) deficiencies
- replacement transfusion with FFP
- no platelet inhibitory drugs